Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director | June 02, 2026 | June 04, 2026 |
| Centessa Pharmaceuticals plcCNTA · Entity 35581 | Director | November 18, 2021 | November 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.96 · Expires 2036-06-02 | Direct | 20,100 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 20,100 · Balance 20,100 F1: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.
Centessa Pharmaceuticals plc
Report date November 18, 2021 · Filed November 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 60,000 |
Reported balance
After 2021-11-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-11-18 · Purchase · Acquired 10,000 · Balance 60,000 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Tourmaline Bio, Inc.
Report date October 28, 2025 · Filed October 28, 2025
Section 16 reporting ended · disclosed 2025-10-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 1
1 source rowRow 1 · 2025-10-28 · Other · Disposed 88,281 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F2: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.91 | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-10-28 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.73 | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-28 · Disposition to issuer · Disposed 16,800 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration").
F2: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share.
F3: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2026 Filed Jun 4, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 20,100 | $0.00 Strike: $13.96 | $0.00 |
DisclosureSEC source: 0001862734-26-000004 · form4-06042026_040605.xml · derivative · entry 1 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2036-06-02 F1 · derivative.exercise_date: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. Read SEC document |
| March 28, 2026 Filed Mar 31, 2026 20:12 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionRestricted Stock Units · Derivative | 3,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001862734-26-000002 · form4-03312026_080342.xml · derivative · entry 2 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,167 Underlying: Common Stock · 3,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. F2 · derivative.expiration_date: On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 28, 2026 Filed Mar 31, 2026 20:12 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 3,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001862734-26-000002 · form4-03312026_080342.xml · nonDerivative · entry 1 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 22:30 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 16,800 | Not disclosed Strike: $18.73 | Not disclosed |
DisclosureSEC source: 0001862734-25-000006 · form4-10282025_061013.xml · derivative · entry 3 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,800 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F3 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 22:30 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $13.91 | Not disclosed |
DisclosureSEC source: 0001862734-25-000006 · form4-10282025_061013.xml · derivative · entry 2 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F3 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 22:30 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | OtherCommon Stock | 88,281 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001862734-25-000006 · form4-10282025_061013.xml · nonDerivative · entry 1 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F2 · price: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share. Read SEC document |
| October 24, 2025 Filed Oct 24, 2025 22:10 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001862734-25-000004 · form4-10242025_101016.xml · nonDerivative · entry 1 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,281 F1 · kind: Shares donated to a donor-advised fund, which will use the gifted shares for charitable purposes. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 22:00 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.46 | $0.00 |
DisclosureSEC source: 0001415889-25-023997 · form4-09092025_060901.xml · derivative · entry 4 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2033-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 22:00 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,890 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001415889-25-023997 · form4-09092025_060901.xml · derivative · entry 3 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,890 shares Expires 2033-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 22:00 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Exercise / conversionCommon Stock | 10,000 | $9.46 | $94,600.00 |
DisclosureSEC source: 0001415889-25-023997 · form4-09092025_060901.xml · nonDerivative · entry 2 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 22:00 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Exercise / conversionCommon Stock | 37,890 | $0.13 | $4,925.70 |
DisclosureSEC source: 0001415889-25-023997 · form4-09092025_060901.xml · nonDerivative · entry 1 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:25 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 20,100 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001578563-25-000321 · primary_doc.xml · derivative · entry 1 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2035-06-17 F1 · derivative.exercise_date: The stock option vests 100% on the first anniversary of the date of grant, subject to the Eligible Director's continued service on such vesting date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:41 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GrantStock Option (Right to Buy) · Derivative | 16,800 | $0.00 Strike: $18.73 | $0.00 |
DisclosureSEC source: 0001827506-25-000084 · wk-form4_1749242441.xml · derivative · entry 1 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,800 Underlying: Common Stock · 16,800 shares Expires 2035-06-04 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 20:37 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionRestricted Stock Units · Derivative | 3,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000201 · primary_doc.xml · derivative · entry 2 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,333 Underlying: Common Stock · 3,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. F2 · derivative.expiration_date: On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 20:37 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 3,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001578563-25-000201 · primary_doc.xml · nonDerivative · entry 1 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:36 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantRestricted Stock Units · Derivative | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000367 · primary_doc.xml · derivative · entry 2 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock upon the vesting date. F3 · derivative.exercise_date: The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. F3 · derivative.expiration_date: The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:36 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 24,600 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001578563-24-000367 · primary_doc.xml · derivative · entry 1 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,600 Underlying: Common Stock · 24,600 shares Expires 2034-08-13 F1 · derivative.exercise_date: The stock option vests 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:02 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.91 | $0.00 |
DisclosureSEC source: 0001827506-24-000054 · wk-form4_1717790566.xml · derivative · entry 1 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| October 24, 2023 Filed Oct 26, 2023 21:00 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | PurchaseCommon Stock | 7,500 | $11.86 | $88,950.00 |
DisclosureSEC source: 0001209191-23-053674 · doc4.xml · nonDerivative · entry 1 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,391 Read SEC document |
| October 23, 2023 Filed Oct 24, 2023 00:24 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.46 | $0.00 |
DisclosureSEC source: 0001209191-23-053397 · doc4.xml · derivative · entry 3 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-10-22 F6 · derivative.exercise_date: 100% of the shares subject to the option vest on the earlier of October 23, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| October 19, 2023 Filed Oct 24, 2023 00:24 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GrantStock Option (Right to Buy) · Derivative | 37,890 | Not disclosed Strike: $0.13 | Not disclosed |
DisclosureSEC source: 0001209191-23-053397 · doc4.xml · derivative · entry 2 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,890 Underlying: Common Stock · 37,890 shares Expires 2033-02-02 F3 · derivative.exercise_price: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F3 · shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F3 · price: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F5 · price: Received in exchange for a stock option to acquire 475,000 shares of Tourmaline common stock pursuant to the Merger Agreement. F4 · derivative.exercise_date: The shares subject to the option vest as to 1/3 of the shares on May 6, 2023 with the remainder vesting in the following 24 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. F3 · derivative.underlying_shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. Read SEC document |
| October 19, 2023 Filed Oct 24, 2023 00:24 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GrantCommon Stock | 37,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-053397 · doc4.xml · nonDerivative · entry 1 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,891 F1 · shares: 2,015 of these shares are subject to a repurchase option in favor of the Issuer in the event that the Reporting Person's continuous service is terminated. Such repurchase option shall lapse in equal monthly installments until such shares are fully vested on June 1, 2026. F2 · price: Received in exchange for 475,000 shares of common stock of Tourmaline Bio, Inc. ("Tourmaline") pursuant to an Agreement and Plan of Merger dated as of June 22, 2023 (the "Merger Agreement") by and among Tourmaline, the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on October 19, 2023, Merger Sub merged with and into Tourmaline (the "Merger"), with Tourmaline surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Tourmaline common stock was converted into the right to receive 0.07977 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 10-for-1. Subsequent to the Merger, the name of the Issuer was changed from Talaris Therapeutics, Inc. to Tourmaline Bio, Inc. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 01:30 UTC | Centessa Pharmaceuticals plc CNTA · Entity 35581 | PurchaseOrdinary Shares | 10,000 | $11.99 | $119,850.00 |
DisclosureSEC source: 0000899243-21-045321 · doc4.xml · nonDerivative · entry 1 KANTOFF AARON · CIK 0001862734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.